UA75867C2 - A method of determining the presence of catalytic factor viii allo-antibodies capable of degrading factor viii in a mammal, amino acid sequence inhibiting any site in factor viii molecule being sensible to cleavage by allo-antibodies in factor viii (variants), use of inhibitor of cleavage of factor viii to neutralize a catalytic activity of allo-antibodies to factor viii and pharmaceutical composition containing allo-antibodies being capable of degrading factor viii - Google Patents

A method of determining the presence of catalytic factor viii allo-antibodies capable of degrading factor viii in a mammal, amino acid sequence inhibiting any site in factor viii molecule being sensible to cleavage by allo-antibodies in factor viii (variants), use of inhibitor of cleavage of factor viii to neutralize a catalytic activity of allo-antibodies to factor viii and pharmaceutical composition containing allo-antibodies being capable of degrading factor viii Download PDF

Info

Publication number
UA75867C2
UA75867C2 UA2002010487A UA2002010487A UA75867C2 UA 75867 C2 UA75867 C2 UA 75867C2 UA 2002010487 A UA2002010487 A UA 2002010487A UA 2002010487 A UA2002010487 A UA 2002010487A UA 75867 C2 UA75867 C2 UA 75867C2
Authority
UA
Ukraine
Prior art keywords
factor
antibodies
allo
factor viii
cleavage
Prior art date
Application number
UA2002010487A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Inst Nat Sante Rech Med
Bayer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Bayer Pharma filed Critical Inst Nat Sante Rech Med
Publication of UA75867C2 publication Critical patent/UA75867C2/uk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
UA2002010487A 1999-07-21 2000-07-18 A method of determining the presence of catalytic factor viii allo-antibodies capable of degrading factor viii in a mammal, amino acid sequence inhibiting any site in factor viii molecule being sensible to cleavage by allo-antibodies in factor viii (variants), use of inhibitor of cleavage of factor viii to neutralize a catalytic activity of allo-antibodies to factor viii and pharmaceutical composition containing allo-antibodies being capable of degrading factor viii UA75867C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401841A EP1074842A1 (en) 1999-07-21 1999-07-21 Catalytic anti-factor VIII allo-antibodies
PCT/EP2000/006870 WO2001007918A1 (en) 1999-07-21 2000-07-18 Catalytic anti-factor viii allo-antibodies

Publications (1)

Publication Number Publication Date
UA75867C2 true UA75867C2 (en) 2006-06-15

Family

ID=8242069

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002010487A UA75867C2 (en) 1999-07-21 2000-07-18 A method of determining the presence of catalytic factor viii allo-antibodies capable of degrading factor viii in a mammal, amino acid sequence inhibiting any site in factor viii molecule being sensible to cleavage by allo-antibodies in factor viii (variants), use of inhibitor of cleavage of factor viii to neutralize a catalytic activity of allo-antibodies to factor viii and pharmaceutical composition containing allo-antibodies being capable of degrading factor viii

Country Status (24)

Country Link
US (2) US7507540B1 (is)
EP (2) EP1074842A1 (is)
JP (2) JP2003505434A (is)
KR (1) KR100788435B1 (is)
CN (1) CN1229646C (is)
AU (1) AU777615B2 (is)
BR (1) BR0012613A (is)
CA (1) CA2379818A1 (is)
CZ (1) CZ2002248A3 (is)
EE (1) EE200200034A (is)
HK (1) HK1044372A1 (is)
HU (1) HUP0201941A3 (is)
IL (1) IL147700A0 (is)
IS (1) IS6238A (is)
MX (1) MXPA02000752A (is)
NO (1) NO20020253L (is)
NZ (1) NZ516702A (is)
PL (1) PL353739A1 (is)
RU (1) RU2258935C2 (is)
SK (1) SK862002A3 (is)
TR (1) TR200200340T2 (is)
UA (1) UA75867C2 (is)
WO (1) WO2001007918A1 (is)
ZA (1) ZA200200351B (is)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
FR2969761A1 (fr) * 2010-12-22 2012-06-29 Lfb Biotechnologies Procede de dosage d'anticorps diriges contre le facteur viii
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) * 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
WO1994011013A1 (en) * 1992-11-13 1994-05-26 Duke University Chimeric blood coagulation proteins
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US5744326A (en) * 1996-03-11 1998-04-28 The Immune Response Corporation Use of viral CIS-acting post-transcriptional regulatory sequences to increase expression of intronless genes containing near-consensus splice sites

Also Published As

Publication number Publication date
PL353739A1 (en) 2003-12-01
AU6824500A (en) 2001-02-13
EP1196782A1 (en) 2002-04-17
IS6238A (is) 2002-01-16
SK862002A3 (en) 2002-06-04
KR100788435B1 (ko) 2007-12-24
NZ516702A (en) 2003-10-31
JP2009292823A (ja) 2009-12-17
BR0012613A (pt) 2002-04-09
HK1044372A1 (zh) 2002-10-18
IL147700A0 (en) 2002-08-14
KR20020042618A (ko) 2002-06-05
CA2379818A1 (en) 2001-02-01
NO20020253L (no) 2002-03-13
US20090208512A1 (en) 2009-08-20
JP2003505434A (ja) 2003-02-12
WO2001007918A1 (en) 2001-02-01
ZA200200351B (en) 2003-03-26
NO20020253D0 (no) 2002-01-17
HUP0201941A2 (en) 2002-10-28
CN1229646C (zh) 2005-11-30
MXPA02000752A (es) 2003-07-14
TR200200340T2 (tr) 2003-01-21
CN1361865A (zh) 2002-07-31
HUP0201941A3 (en) 2005-01-28
EP1074842A1 (en) 2001-02-07
EE200200034A (et) 2003-06-16
US7507540B1 (en) 2009-03-24
CZ2002248A3 (cs) 2002-07-17
AU777615B2 (en) 2004-10-21
RU2258935C2 (ru) 2005-08-20

Similar Documents

Publication Publication Date Title
CN102316893B (zh) 因子Xa抑制剂的解毒剂及其与血液凝固剂组合使用的方法
CN105008397B (zh) 作为治疗试剂的Gla结构域
BRPI0816837A2 (pt) antídotos para inibidores do fator xa e métodos para sua utilização
US4980279A (en) Cellular fibronectin: polypeptides, anti-polypeptide antibodies and assay methods
US20080118933A1 (en) Methods of screening for inhibitors of antiplasmin cleaving enzyme
JPH08506181A (ja) 新規抗凝固性補助因子活性
JP2009292823A (ja) 触媒活性抗ｖｉｉｉ因子アロ抗体
TWI774717B (zh) 老年性黃斑部變性症治療用肽及其製造方法
CA1335800C (en) Synovial phospholipases
US7695923B2 (en) CFTR polypeptides methods to overcome biosynthetic misprocessing
Ialenti et al. Synthesis of novel anti‐inflammatory peptides derived from the amino‐acid sequence of the bioactive protein SV‐IV
Citarella et al. Control of human coagulation by recombinant serine proteases: Blood clotting is activated by recombinant factor XII deleted of five regulatory domains
JP4995399B2 (ja) 切断されたｂａｒｄ１タンパク質、並びにその診断上及び治療上の利用
US20100212030A1 (en) Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
JP4767869B2 (ja) Ｃｄ３８スプライスバリアント及びその使用
WO1991004276A1 (en) Isolated, physiologically active human thrombomodulin polypeptide
US20080057491A1 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
CN114981661A (zh) 用于诊断与嗜中性粒细胞胞外陷阱相关的纤溶功能不全的方法
MX2008015649A (es) Sustratos e inhibidores de enzima de escision de antiplasma y metodos de uso.
US6232089B1 (en) CD23 processing enzyme preparation
US8071348B2 (en) Protein tyrosine phosphatase substrate-trapping double mutant and uses thereof
US7666981B1 (en) Inhibitors of prostasin